Periowave : A New Treatment for Periodontal Disease
Does anybody have any thoughts regarding Periowave, a new periodontal treatment recently approved for sale in Canada? According to Ondine Biopharma, the manufacturer, Periowave (TM) is a topical photodynamic disinfection treatment for periodontal diseases.
At the Ondine´s website one can find the following information:
PERIOWAVE : How it worksOndine´s proprietary treatment, Periowave uses a novel non-antibiotic approach for treating the underlying infection responsible for periodontal disease. After routine scaling, the dentist will apply the compound directly into the periodontal pockets and around the gum line of affected teeth. The compound quickly penetrates the plaque preferentially binding to multiple structural components in bacteria, including their toxic secretions. Laser light is then applied directly to the affected sites using a fibre optic probe. A powerful free-radical reaction destroys the targeted bacteria and the associated toxins such as collagenase. The procedure is expected to take under 20 minutes to complete for the entire mouth. Little or no pain will be involved, a significant advantage over current traditional treatments. Additionally, treatments will generally be administered by hygienists.
The PERIOWAVE Advantage:Current therapies for oral-cavity disinfection include antibiotics and antiseptics. Antibiotics are less effective in the oral cavity as they must stay uncomfortably in place for long periods of time, frequently resulting in patient non-compliance. Ondine´s periowave treatment can be applied, activated, and then removed from the affected site, maximizing patient comfort. The benefits of this technology include:
* Rapid action
* Broad-spectrum efficacy
* High specificity to disease-causing bacteria, and
* Low levels of toxicity to host cells in vitro
During September 2005, Ondine announced that it had successfully completed the first human study of its Periowave (TM) photodynamic disinfection (PDD) system, in patients with chronic periodontitis (gum disease). This clinical study was a randomized, controlled study comparing Scaling and Root Planing (SRP) alone to Ondine's adjunctive photodynamic disinfection therapy. The addition of Periowave (TM) to SRP resulted in a statistically and clinically significant improvement in the primary endpoint, the periodontal attachment level.
In addition, Ondine recently established a Sales and Marketing division that will support the Canadian distribution alliance with Henry Schein Ash Arcona, the Canadian subsidiary of Henry Schein, the largest distributor of healthcare products to office-based practitioners. Henry Schein serves approximately 80% of the Canadian and United States office-based dental practices and dental laboratories.
Have any thoughts or comments regarding Periowave? Please leave them below.
Comments
I looked at the company's website. The pilot study that led to approval was 9/05 but I don't see anywhere that even the abstract was published. There's no statistics in the press release--just things like 155% better, but I can't tell if that's 1mm vs 1.4 mm or what. It's also a little curious that it's been 1 1/2 years and I've never even heard of it. They compared it to SRP but I'd like to see what SRP plus the laser did compared to their photoactive solution with SRP and the laser. The biology makes some sense, but it will still have the problem of the laser reaching every bacterial cell to be truly bacteriocidal.
Posted by: Cindy | March 7, 2006 09:04 PM
Good day Cindy,
On behalf of Ondine Biopharma Corp I would like thank you for your interest in our technology. A lot has happened since we posted the information you cite on our website. Please check out www.periowave.com for more information on the technology and product. The study that you reference was accepted for publication by the IADR and will be presented as an abstract at the Florida meeting this week (March 9-10, 2006).
In addition, Ondine has launched numerous studies in the USA, Canada and UK at leading Perio schools.
We are very excited about the clinical results of Photodynamic Disinfection and the Periowave? System and we recognize the need for more scientific data. As more studies are completed and published we look forward to your comments.
Currently, Health Canada has granted Ondine a class II medical device license for the treatment of chronic periodontal disease. Our company has achieved a number of milestones with regards to design, safety and efficacy (base on the study data) and we are truly excited to launch this product in Canada this month.
If you or your colleagues would like more information, feel free to email us at info@periowave.com
Best regards,
Dean Desrosiers
Director of Marketing, Ondine Biopharma Corp.
Posted by: Dean Desrosiers | March 8, 2006 12:38 PM
This is so interesting.....Kill the bugs and stop the disease. I am sure we all understand that the host resistance is the key. There are patients, no matter what you do, the bone goes away. The question for me has always been...even with perfect plaque control unless the pockets are disinfected..bone loss. All companies...Perio Chip et all are fighting at the pocket level. The patients are resistant to talking Periostat, Doxy for long periods and certainly the vitamin thing is not doing it.
I for one are very interested in more information.
Has anyone placed Arestine around the neck portion of the implant are time of placement with a healing abutment through the tissue or immediate load?
Posted by: Jeffrey Hoos DMD | March 10, 2006 07:48 AM
From what I read in the article, it's also the collagenase that's being destroyed and we all know how this inflammatory response destroys tissue in the immune compromised patient. If it does what it claims to do , this would be great for the poorly controlled Diabetic.
Posted by: Kitty Cashman RDH | March 28, 2006 04:00 PM